Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BON Bon Natural Life	$1.41 +1.4%	$1.38	$1.14 ▼ $73.75	$235K	-0.47	1.73 million shs	34,326 shs
PPCB Propanc Biopharma	$3.23 +9.9%	$5.44	$1.25 ▼ $145.46	$37.51M	2.78	872,730 shs	539,506 shs
TRVN Trevena	$0.00 -99.6%	$0.72	$0.00 ▼ $7.85	$1K	0.41	2,131 shs	18,574 shs
VINC Vincerx Pharma	$0.04 -14.6%	$0.04	$0.03 ▼ $17.00	$227K	1.71	559,066 shs	50,569 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BON Bon Natural Life	0.00%	+6.92%	-0.71%	-12.58%	-96.96%
PPCB Propanc Biopharma	-2.97%	-33.18%	-48.50%	-6.67%	+587,900.00%
TRVN Trevena	0.00%	0.00%	-69.78%	-75.56%	-94.01%
VINC Vincerx Pharma	-15.36%	+36.29%	+9.74%	+5.19%	-99.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BON Bon Natural Life	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	1.2418 of 5 stars	3.0	2.0	0.0	0.0	0.0	0.0	0.6
VINC Vincerx Pharma	2.3582 of 5 stars	3.5	3.0	0.0	0.0	0.0	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BON Bon Natural Life	0.00	N/A	N/A	N/A
PPCB Propanc Biopharma	0.00	N/A	N/A	N/A
TRVN Trevena	2.00	Hold	$5.00	416,566.67% Upside
VINC Vincerx Pharma	3.00	Buy	$40.00	92,278.75% Upside

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BON Bon Natural Life	$23.84M	0.01	$1.81 per share	0.78	$37.78 per share	0.04
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	($493.34) per share	N/A
TRVN Trevena	$443K	0.00	N/A	N/A	($11.07) per share	0.00
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	$10.50 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BON Bon Natural Life	$400K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
PPCB Propanc Biopharma	-$1.82M	N/A	0.00	∞	N/A	N/A	-3,652.66%	-971.09%	N/A
TRVN Trevena	-$40.29M	-$47.04	N/A	N/A	N/A	N/A	N/A	-119.55%	11/5/2025 (Estimated)
VINC Vincerx Pharma	-$40.16M	-$20.60	N/A	N/A	N/A	N/A	-248.33%	-132.73%	8/28/2025 (Estimated)

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BON Bon Natural Life	N/A	N/A	N/A	N/A	N/A
PPCB Propanc Biopharma	N/A	N/A	N/A	N/A	N/A
TRVN Trevena	N/A	N/A	N/A	N/A	N/A
VINC Vincerx Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BON Bon Natural Life	0.02	2.42	2.32
PPCB Propanc Biopharma	0.01	2.24	2.24
TRVN Trevena	N/A	2.42	2.42
VINC Vincerx Pharma	N/A	2.17	2.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BON Bon Natural Life	0.57%
PPCB Propanc Biopharma	N/A
TRVN Trevena	13.56%
VINC Vincerx Pharma	44.02%

Insider Ownership

Company	Insider Ownership
BON Bon Natural Life	26.48%
PPCB Propanc Biopharma	0.10%
TRVN Trevena	2.70%
VINC Vincerx Pharma	15.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BON Bon Natural Life	100	167,000	863,000	Not Optionable
PPCB Propanc Biopharma	1	11.61 million	19,000	Not Optionable
TRVN Trevena	40	959,000	841,000	Optionable
VINC Vincerx Pharma	60	5.23 million	1.89 million	Not Optionable

PPCB, TRVN, BON, and VINC Headlines

Recent News About These Companies

Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders ...

July 16, 2025 | gurufocus.com

Vincerx Pharma, Inc. Announces Additional Adjournment of Special Meeting - Urges Stockholders to Vote FOR Approval of Dissolution Proposal

July 16, 2025 | globenewswire.com

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders | The ... - The Manila Times

July 9, 2025 | manilatimes.netM

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders - Morningstar

July 9, 2025 | morningstar.comM

Vincerx Pharma, Inc. Common Stock (VINC) - Yahoo Finance

July 8, 2025 | finance.yahoo.com

Vincerx Pharma, Inc. Urges Stockholders to Vote FOR Approval of Dissolution Proposal and Announces Potential Range for Distributions to Stockholders

July 7, 2025 | globenewswire.com

Vincerx Pharma, Inc. (VINC) - Yahoo Finance

July 2, 2025 | ca.finance.yahoo.com

Vincerx Pharma, Inc. Announces Adjournment of Special Meeting - Will Reconvene Meeting on July 16, 2025 to Secure Votes Needed to Approve Dissolution Proposal

June 18, 2025 | globenewswire.com

Vincerx Pharma announces plan to delist from Nasdaq

April 18, 2025 | markets.businessinsider.com

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

April 17, 2025 | finance.yahoo.com

Vincerx Pharma, Inc. Announces Intent to Delist from Nasdaq and Deregister with the SEC

April 17, 2025 | globenewswire.com

Vincerx's final merger attempt collapses, leaving ADC biotech to wind down

April 9, 2025 | fiercebiotech.comF

Vincerx terminates letter of intent with Global Digital, initiates wind down

April 9, 2025 | markets.businessinsider.com

Financially struggling drugmaker's potential rescue falls apart. It now will wind down

April 9, 2025 | bizjournals.com

Vincerx Pharma Announces Termination of Letter of Intent and Board Authorization to Pursue Wind-Down Activities

April 8, 2025 | globenewswire.com

Vincerx Pharma announces non-binding LOI for Qumulus AI combination

March 18, 2025 | markets.businessinsider.com

Vincerx Pharma, Inc.: Vincerx Pharma Announces Non-Binding Letter of Intent for Business Combination with QumulusAI

March 18, 2025 | finanznachrichten.de

Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis

March 18, 2025 | fiercebiotech.comF

Vincerx Pharma Shares Soar on Proposed Merger with Global Digital Holdings

March 18, 2025 | marketwatch.com

Vincerx Pharma, Inc. Announces Non-Binding Letter of Intent for Business Combination with QumulusAI

March 18, 2025 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

PPCB, TRVN, BON, and VINC Company Descriptions

Bon Natural Life NYSE:BON

$1.41 +0.02 (+1.44%)

Closing price 03:53 PM Eastern

Extended Trading

$1.40 -0.01 (-1.06%)

As of 04:02 PM Eastern

Bon Natural Life Limited, together with its subsidiaries, engages in the research and development, manufacture, and sale of functional active ingredients extracted from natural herb plants in the People's Republic of China and internationally. It offers personal care ingredients, such as plant extracted fragrance compounds to perfume and fragrance manufacturers; and natural health supplements comprising powder drinks and bioactive food ingredient products used as food additives and nutritional supplements. Its products are used by manufacturer customers in the functional food, personal care, cosmetic, and pharmaceutical industries. The company was founded in 2006 and is based in Xi'an, the People's Republic of China.

Propanc Biopharma OTCMKTS:PPCB

$3.23 +0.29 (+9.86%)

As of 03:42 PM Eastern

Propanc Biopharma, Inc., a biopharmaceutical company, develops cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. It offers PRP, a formulation lead product that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes. The company has a research collaboration with University of Jaén that undertakes the research activities for POP1 joint drug discovery program; and a joint research and drug discovery program with Universities of Jaén and Granada to investigate the changes in genetic and protein expression that occur in cancer cells. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was incorporated in 2007 and is based in Camberwell, Australia.

Trevena NASDAQ:TRVN

$0.0012 -0.27 (-99.56%)

As of 11:38 AM Eastern

Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.

Vincerx Pharma NASDAQ:VINC

$0.04 -0.01 (-14.60%)

As of 03:10 PM Eastern

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time